These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35532193)

  • 1. Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.
    Ahn SH; Ahn SS; Park YW; Park CJ; Lee SK
    Neuroradiol J; 2023 Feb; 36(1):49-58. PubMed ID: 35532193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
    Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
    Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
    Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
    Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.
    Park YW; Ahn SS; Moon JH; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Neuroradiology; 2021 Nov; 63(11):1811-1822. PubMed ID: 33755766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II-III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI.
    Wang X; Cao M; Chen H; Ge J; Suo S; Zhou Y
    Radiol Oncol; 2020 Jun; 54(3):301-310. PubMed ID: 32559177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
    Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
    Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
    Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
    Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study.
    Di N; Cheng W; Jiang X; Liu X; Zhou J; Xie Q; Chu Z; Chen H; Wang B
    J Neuroradiol; 2019 May; 46(3):186-192. PubMed ID: 29752976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
    Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
    Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.
    Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM
    Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.